Khaled SAAD, Zeinab M. MOHY-ELDEEN, Ahmad R. AHMAD, Hayam H. MAHRAN

Comparative study of various therapeutic modalities for Guillain Barré syndrome in Assiut University Children Hospital

Background. Our study aimed to compare the outcome of different therapeutic modalities for the management of children with Guillain-Barré syndrome (GBS) and to identify the associating risk factors that may affect the course and prognosis of the disease. Methods. Our retrospective study compared the outcomes of different therapeutic regimens for patients with GBS who were admitted to Assiut University Children Hospital, Assiut, Egypt, from 2014 to 2016. Results. The study included 50 patients diagnosed with GBS. Upper respiratory tract infection was the most prevalent preceding factor (66%). Acute inflammatory demyelinating polyneuropathy (AIDP) was the most prevalent type (80%). Regarding therapeutic modalities, 45 patients started with IVIG treatment, and five patients started plasmapheresis. Seventeen patients showed no improvement after two weeks of IVIG and received plasmapheresis as a sequential therapy. We found no patients who received plasmapheresis, followed by IVIG. Patients treated with plasmapheresis alone showed a significantly shorter duration of hospitalization and better outcomes in comparison to those treated with IVIG alone or with both modalities. Conclusions. AIDP was the most common variety of GBS in our study. GBS patients who were treated with plasmapheresis had a better outcome with a short duration of hospitalization.

PDF

___

1. Rosen BA. Guillain-Barré syndrome. Pediatr Rev 2012; 33: 164-170.
2. Pavone P, Praticò AD, Ruggieri M, et al. Acquired peripheral neuropathy: a report on 20 children. Int J Immunopathol Pharmacol 2012; 25: 513-517.
3. Alexander M, Prabhakar AT, Aaron S, Thomas M, Mathew V, Patil AK. Utility of neurophysiological criteria in Guillain-Barré syndrome: subtype spectrum from a tertiary referral hospital in India. Neurol India 2011; 59: 722-726.
4. Yuki N, Hartung HP. Guillain–Barré syndrome. N Engl J Med 2012; 366: 2294-2304.
5. van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 2014; 10: 469-482.
6. Sejvar JJ, Kohl KS, Gidudu J, et al; Brighton Collaboration GBS Working Group. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011; 29: 599- 612.
7. Raphael JC, Chevret S, Jars-Guincestre MC, Chastang C, Gajdos P. Treatment of Guillain-Barré syndrome by plasma exchange: proposal of a therapeutic strategy. Rev Neurol (Paris) 1996; 152: 359-364.
8. The Guillain–Barré syndrome Study Group. Plasmapheresis and acute Guillain–Barré syndrome. Neurology 1985; 35: 1096-1104.
9. Saad K, Mohamad IL, Abd El-Hamed MA, et al. A comparison between plasmapheresis and intravenous immunoglobulin in children with Guillain-Barré syndrome in Upper Egypt. Ther Adv Neurol Disord 2016; 9: 3-8.
10. Sipilä JOT, Soilu-Hänninen M, Ruuskanen JO, Rautava P, Kytö V. Epidemiology of Guillain-Barré syndrome in Finland 2004-2014. J Peripher Nerv Syst 2017; 22: 440-445.
11. Webb AJS, Brain SAE, Wood R, Rinaldi S, Turner MR. Seasonal variation in Guillain-Barré syndrome: a systematic review, meta-analysis and Oxfordshire cohort study. J Neurol Neurosurg Psychiatry 2015; 8611: 1196-1201.
12. Dhadke SV, Dhadke VN, Bangar SS, Korade MB. Clinical profile of Guillain-Barré syndrome. J Assoc Physicians India 2013; 61: 168-172.
13. Wu X, Shen D, Li T, et al. Distinct clinical characteristics of pediatric Guillain-Barré syndrome: a comparative study between children and adults in Northeast China. PLoS One 2016; 11: e0151611.
14. Koul RL, Alfutaisi A. Prospective study of children with Guillain-Barré syndrome. Indian J Pediatr 2008; 75: 787-790.
15. Mossberg N, Nordin M, Movitz C, et al. The recurrent Guillain-Barré syndrome: a long-term population-based study. Acta Neurol Scand 2012; 126: 154-161.
16. McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain–Barré syndrome worldwide. A systematic literature review. Neuroepidemiology 2009; 32: 150-163.
17. Tang J, Dai Y, Li M, et al. Guillain-Barré syndrome in Chinese children: a retrospective analysis. Pediatr Neurol 2011; 45: 233-237.
18. Kuwabara S, Mori M, Ogawara K, et al. Intravenous immunoglobulin therapy for Guillain- Barré syndrome with IgG anti-GM1 antibody. Muscle Nerve 2001; 24: 54-58.
19. Diener HC, Haupt WF, Kloss TM, et al. A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome. Eur Neurol 2001; 46: 107-109.
20. Oczko-Walker M, Manousakis G, Wang S, Malter JS, Waclawik AJ. Plasma exchange after initial intravenous immunoglobulin treatment in GuillainBarré syndrome: critical reassessment of effectiveness and cost-efficiency. J Clin Neuromuscul Dis 2010; 12: 55-61.
21. Hu MH, Chen CM, Lin KL, et al. Risk factors of respiratory failure in children with Guillain-Barré syndrome. Pediatr Neonatol 2012; 53: 295-299.
22. Varkal MA, Uzunhan TA, Aydınlı N, Ekici B, Çalışkan M, Özmen M. Pediatric Guillain-Barré syndrome: indicators for a severe course. Ann Indian Acad Neurol 2015; 18: 24-28.